又一家“A+H”医药巨头！恒瑞医药启动港股超百亿募资

Core Viewpoint - Heng Rui Medicine officially launched its H-share global public offering on May 15, aiming to issue 225 million H-shares with a price range of HKD 41.45 to HKD 44.05, potentially raising up to HKD 130.8 billion, which could be the largest IPO in the Hong Kong pharmaceutical sector in the past five years [1][3][4] Group 1: IPO Details - The offering consists of 5.5% for public sale in Hong Kong and 94.5% for international placement, with a potential total issuance of 297 million shares if the over-allotment option is fully exercised [3] - The net proceeds from the fundraising will be used for R&D plans, building new production and R&D facilities in China and overseas, upgrading existing facilities, and general corporate purposes [3][4] - The cornerstone investors include notable international institutions such as GIC, Invesco, and UBS-GAM, securing nearly HKD 41 billion in subscriptions, accounting for 43.04% of the offering size [1][4] Group 2: Strategic Importance - The IPO is a critical step in Heng Rui Medicine's "innovation + internationalization" dual-drive strategy, enhancing its brand influence in the global pharmaceutical industry [4][5] - The listing is expected to optimize the company's capital structure and open new financing channels, aiding in the diversification of funding sources [5] - It will also facilitate the expansion of overseas business and international R&D collaborations, thereby enhancing global competitiveness [5] Group 3: Future Prospects - Heng Rui Medicine anticipates 47 innovative products to be approved for market launch in the next three years, including significant products like HER2ADC and GLP-1 drugs [6] - The company has established various technology platforms and is conducting over 400 clinical trials, with 19 innovative drugs already approved in China [6] - The IPO is expected to broaden financing channels, accelerate new drug development, and enhance international competitiveness, creating favorable conditions for the commercialization of key products [7]